Bill
HR 4392
HR 4392 enhances treatment options and access for uterine fibroids, funding research and awareness campaigns to improve gynecological health for affected individuals.
The Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025 (HR 4392) aims to address the growing concerns surrounding uterine fibroids and overall gynecological health. Introduced in the House on July 15, 2025, the bill seeks to enhance treatment options and improve healthcare access for individuals affected by these conditions.
The primary purpose of HR 4392 is to:
- Improve Treatment Options: Expand and promote interventions for uterine fibroids, which are noncancerous growths in the uterus that can cause significant discomfort and health issues.
- Enhance Gynecological Health: Foster better overall gynecological health through increased awareness, research funding, and healthcare accessibility for affected individuals.
While the bill is currently in its introductory stage, the following key elements are anticipated based on similar legislative efforts:
- Funding for Research: Allocation of federal funds to support research on uterine fibroids and related gynecological conditions.
- Healthcare Access: Initiatives to improve access to treatment options, including minimally invasive procedures and alternative therapies.
- Public Awareness Campaigns: Development of educational programs aimed at increasing awareness about uterine fibroids and available treatment options.
The bill is expected to impact:
- Patients: Individuals suffering from uterine fibroids and other gynecological health issues will benefit from improved treatment options and resources.
- Healthcare Providers: Medical professionals will receive guidance and support for managing uterine fibroid cases and enhancing patient care.
- Researchers: Increased funding and focus on research will provide opportunities for advancements in understanding and treating uterine fibroids.
HR 4392 is supported by a diverse group of sponsors and cosponsors, including:
- Primary Sponsor: Shontel M. Brown
- Notable Cosponsors:
- LaMonica McIver
- Yassamin Ansari
- Ro Khanna
- Sydney Kamlager-Dove
- Jahana Hayes
- Al Green
- Valerie P. Foushee
- And many others, totaling over 30 cosponsors.
The Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025 represents a significant step towards addressing the challenges posed by uterine fibroids and improving gynecological health. As the bill progresses through the legislative process, it holds the potential to bring about meaningful changes in treatment access and healthcare outcomes for affected individuals.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
